



December 5, 2013

VIA E-MAIL

Ms. Melissa Jurgens
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

RE:

SUPPLEMENTAL SUBMISSION: CME Submission No. 13-426S: Additional Supplemental Information Relating to the CME Eurodollar Futures and Options Market Maker Tier Incentive Program CME Futures and Options

Tier Aggregation.

Subject to a Freedom of Information Act Protection.

Dear Ms. Jurgens:

Previously, pursuant to Submission No. 13-426 dated December 5, 2013, Chicago Mercantile Exchange Inc. ("CME" or "Exchange") notified the Commodity Futures Trading Commission ("CFTC" or "Commission") of plans to extend the CME Eurodollar Futures and Options Market Maker Tier Incentive Program CME Futures and Options Tier Aggregation ("Program").

Please note, we are changing the name of the Program from "CME Eurodollar Futures and Options Market Maker Tier Incentive Program" to "CME Futures and Options Tier Aggregation." All other Program terms remain unchanged.

In this letter, the Exchange is providing the Commission with certain additional information related to the incentives under the Program. The additional supplemental information is provided in Appendix A, for which a request for confidential treatment and detailed written justification is being simultaneously submitted to the Commission. A copy of that request for confidential treatment and detailed written justification is included with this supplemental filing.

CME certifies that the Program complies with the Commodity Exchange Act ("CEA") and the regulations thereunder. A concise explanation and analysis of the operation, purpose and effect of the Program was provided in Submission No. 13-426. There were no substantive opposing views to this Program.

The Exchange certifies that a description of this submission has been concurrently posted on the Exchange's website at http://www.cmegroup.com/market-regulation/rule-filings.html.


If you require any additional information regarding this submission, please contact Tim Elliott at 312-466-7478 or via e-mail at tim.elliott@cmegroup.com, or contact me at 212-299-2200. Please reference our CME Submission No. 13-426 in any related correspondence.

Sincerely,

/s/ Christopher K. Bowen
Managing Director and Chief Regulatory Counsel

Attachment: Appendix A

1 North End Avenue New York, NY 10282 if 212 299 2200 if 212 299 2299 christopher bowen@cmegroup.com cmegroup.com





December 5, 2013

VIA E-MAIL

Ms. Melissa Jurgens
Office of the Secretariat
Commodity Futures Trading Commission
Three Lafayette Centre
1155 21st Street, N.W.
Washington, D.C. 20581

Re: FOIA Confidential Treatment Request

Dear Ms. Jurgens:

By e-mail dated today, December 5, 2013, Chicago Mercantile Exchange Inc. ("CME" or "Exchange") submitted a supplemental rule certification filing (Submission No. 13-426S) to the Commodity Futures Trading Commission ("CFTC" or "Commission"). This supplemental filing includes an appendix ("Appendix A"), which is attached.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), the Exchange requests confidential treatment of Appendix A, on the grounds that Appendix A contains confidential commercial information of the submitter (CME). A detailed written justification supporting this request is attached hereto as Exhibit 1. Pursuant to Commission Regulation 145.9(d)(5), the Exchange requests that confidential treatment be maintained for Appendix A until further notice from the Exchange. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose such Appendix A to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. The Exchange does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/ Christopher K. Bowen Managing Director and Chief Regulatory Counsel

Enclosure:

Exhibit 1